Q Financial Update November 6, 2018 NASDAQ:FPRX

Size: px
Start display at page:

Download "Q Financial Update November 6, 2018 NASDAQ:FPRX"

Transcription

1 Q Financial Update November 6, 2018 NASDAQ:FPRX

2 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation, progress and scope of clinical trials for Five Prime s product candidates; (ii) the potential use of our Five Prime s product candidates, including in combination with other products, to treat certain patients; (iii) the extent of protein overexpression in certain patient populations and the number of potential patients eligible for treatment with our products; (iv) the prevalence and incidence of certain diseases; (iv) the timing of the presentation of data for Five Prime s product candidates; (vi) the date David V. Smith will join Five Prime as Executive Vice President and Chief Financial Officer; (vii) Five Prime s full-year 2018 net cash used in operating activities; and (viii) the amount of Five Prime s cash, cash equivalents and marketable securities at the end of Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during research, preclinical or clinical studies, changes in expected or existing competition, changes in the regulatory, pricing or reimbursement environment, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forwardlooking statements in this press release are discussed in Five Prime s filings with the U.S. Securities and Exchange Commission, including the Risk Factors contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

3 Five Prime Highlights Bemarituzumab (FGFR2b antibody; FPA144) o o Initiated patient dosing in the randomized, controlled Phase 3 FIGHT trial of bemarituzumab with chemotherapy in front-line gastric and GEJ cancer. Present data from the Phase 1 safety lead-in of the FIGHT trial at ASCO GI conference. Cabiralizumab (CSF1R antibody; FPA008) o o o BMS is enrolling patients in a randomized Phase 2 trial evaluating cabiralizumab + OPDIVO as a 2 nd -line treatment in ~160 patients with pancreatic cancer. Stand Up To Cancer and BMS are supporting a randomized Phase 2 front-line maintenance trial (GemCaN) to test if cabiralizumab + OPDIVO can provide prolonged disease control in patients with advanced pancreatic cancer compared to gemcitabine alone. Apexigen and BMS are supporting a Phase 1/1b trial evaluating APX005M (anti-cd40) + cabiralizumab + OPDIVO in patients with melanoma, non-small cell lung cancer or renal cell carcinoma whose disease has progressed on a prior regimen containing a PD-1 or PD-L1 inhibitor without intervening therapy. FPA150 (B7-H4 antibody) o o o Initiated dosing in an exploratory basket cohort of patients with tumors that overexpress B7-H4 to investigate FPA150 monotherapy at doses that have shown efficacy in preclinical models. Phase 1a dose escalation in solid tumors is ongoing; dosing in seventh of eight expected cohorts. Phase 1b dose expansion in patients whose tumors overexpress B7-H4 (HR+/HER2- and triple negative breast cancers, ovarian cancer and endometrial cancer) will follow completion of Phase 1a. o Anticipate presenting Phase 1 data at a medical conference in FPT155 (CD80-Fc) o Opened enrollment in the dose escalation portion of a Phase 1a/1b trial in Australia. BMS (TIM-3 antibody) o BMS Phase 1/2 trial is testing BMS both as a single agent and in combination with OPDIVO. o BMS to present preclinical poster at SITC conference. 3

4 4 Oncology-Focused Pipeline with Multiple Clinical Candidates Program Collaborator Bemarituzumab (FPA144) FGFR2b ANTIBODY Cabiralizumab (FPA008) CSF-1R ANTIBODY FIGHT trial (with chemo) in gastric/gej cancer 2L pancreatic cancer trial (with OPDIVO and chemo) Phase 2 1L maintenance Stand Up to Cancer and BMS supported trial (with OPDIVO) Phase 2 Phase 3 Multiple tumor settings (with OPDIVO) Apexigen & BMS supported trial for APX005M (anti-cd40) and cabira and OPDIVO Phase 1 Phase 1 BMS TIM-3 ANTIBODY Phase 1/2 trial in multiple tumor settings Phase 1 FPA150 B7-H4 ANTIBODY Multiple tumor settings Phase 1a FPT155 CD80-Fc FUSION Multiple tumor settings Phase 1a I-O antibodies Multiple tumor settings Pre-IND Novel I-O biologics Multiple tumor settings Lead Generation

5 Attractive Commercial Opportunity for Bemarituzumab in Front-Line Treatment of FGFR2b+ Gastric and GEJ Cancer 5 Estimated Addressable Metastatic Gastric and GEJ Adenocarcinoma Patients 1 US EU Japan/Korea China 1 st line patients 28, , , ,000 Treatment eligible (10% FGFR2b+) Patients treated with systemic therapy 2,840 15,300 13,430 47,400 2,050 11,020 9,670 34,130 Global pricing for recently launched biologics range ~$6,500 to >$14,000/month 1 Median PFS of FOLFOX alone in front-line gastric cancer treatment: 6-7 months 2 Median OS of FOLFOX alone in front-line gastric cancer treatment: months 2 Unmet need: FGFR2b+ patients have significantly reduced survival 3 1) Internal estimates based on population, published incidence and recurrence rates and estimated treatment rates, CancerMPact Kantar Health, Accessed October ) Yoon et al. J Clin Oncol Shah et al. JAMA Oncol Al-Batran SE et al. J Clin Oncol ) Jung et al Hattori et al

6 Attractive Market Opportunity for Cabira: Unresectable or Metastatic Pancreatic Cancer in Major Markets 6 Incidence (2016) 1 US EU5* Japan First-line 45,950 52,130 32,240 Second-line 22,827 26,049 15,618 Sources: 1 - Decision Resources Group; Pancreatic Cancer Epidemiology Overview, August * - EU5 = France, Germany, Italy, Spain, UK

7 FPA150: Opportunity to Address Large Patient Populations with High Unmet Medical Need 7 Late-line Treatment Estimated Eligible Population 1 US EU5 Japan TNBC 3L+ 5,170 5,230 2,000 HR+/HER2- Breast Hormone-refractory and 3L chemo+ Ovarian 2L+ platinum-resistant Endometrial 2L+ Estimated Addressable Patients and Unmet Need 45,800 49,560 14,200 10,740 10,970 3,730 Late-line data not available Historical mpfs 2 < 4 months Potential to expand to earlier lines of therapy in combination with standard of care (e.g., PD-(L)1 therapy, chemotherapy, PARP inhibitors) 1 Decision Resources Group 2018, 2 Twelves C, Breast Cancer: Basic and Clinical Research 2016, 3 Mutch DG, J Clin Oncol 2007, 4 Aghajanian C, J Clin Oncol 2011, 5 Powels T, Lancet 2018

8 Bemarituzumab (FPA144) Was Designed to Recruit Tumor-Killing NK Cells into the Tumor Microenvironment and Block Growth Factor Ligands 8 Natural Killer Cell Enhanced ADCC to increase NK cell recruitment Bema FGFR2b FGF7, 10, 22 Specific to FGFR2b splice variant; blocks growth factor ligands Tumor Cell

9 FIGHT Phase 3 Trial of Bemarituzumab in Front-Line FGFR2b+ Gastric and GEJ Cancer 9 Randomized Phase 3 ~550 patients Initiated September 2018 Bema + mfolfox6 vs Placebo + mfolfox6 Study Endpoints OS PFS ORR FGFR2b overexpression and FGFR2 gene amplification associated with worse prognosis ~10% of gastric and GEJ cancer patients expected to be biomarker-positive Select patients by IHC (tumor sample) or ctdna (blood-based) tests

10 Cabiralizumab, a Product of the Five Prime Platform, Blocks Survival of Macrophages 10 Cabiralizumab (FPA008) is an antibody to CSF-1R CSF-1 IL-34 Five Prime discovered IL-34, one of the two ligands for CSF-1R that cabiralizumab (FPA008) blocks

11 Durable Responses Observed Without Chemo in Late-Line Pancreatic Cancer* Percent change in tumor burden (SLD) from baseline 11 Best change in tumor burden over time in efficacy-evaluable patients treated with cabiralizumab 4 mg/kg + nivolumab 3 mg/kg (n=31) Progressive disease Treated beyond progressive disease Partial response Day Efficacy & Safety: Durable clinical benefit observed Confirmed ORR = 13% DCR = 16% Disease control: 5 to 9+ months Heavily pretreated population (average 3 prior therapies) All responders had microsatellite stable tumors (do not respond to PD1/L1 therapy) No new or additive safety signals identified Whole exome sequencing analysis demonstrated that nearly all patients had low TMB Days * SITC, November 2017 Wainberg Z, et al.

12 BMS-Sponsored Randomized, Open-Label Phase 2 Trial of Cabiralizumab/OPDIVO in 2 nd -Line Pancreatic Cancer (NCT ) 12 Prior Line: Gemcitabine-Based Chemotherapy Trial Arms (2 nd -Line) Arm A: Chemotherapy alone Gemcitabine/Abraxane or 5-FU/leucovorin/Onivyde Arm B: Cabiralizumab + OPDIVO N ~160 patients Study Objectives Progression free survival (primary) Objective response rate and duration Prior Line: 5-Fluorouracil-Based Chemotherapy Arm C: Cabiralizumab + OPDIVO combined with gemcitabine + Abraxane Arm D: Cabiralizumab + OPDIVO combined with oxaliplatin/5-fu/leucovorin Overall survival rate Safety PK First patient dosed January 2018 Study will generate data that could support a front-line or second-line pivotal study

13 13 FPA150 Has Two Mechanisms: Block the Checkpoint and Enhance ADCC Enhanced NK-mediated cell killing (ADCC) FPA150 B7-H4 T Cell B7-H4 Tumor Cell B7-H4 FPA150 Blocks B7-H4 checkpoint activity

14 B7-H4 is Expressed in Multiple Solid Tumors Not Well Served by Checkpoint Inhibitors 14 Expression Levels N e g a t i v e M o d e r a t e - H i ( ~ 6 0 % ) N e g a t i v e M o d e r a t e - H i ( ~ 5 0 % ) N e g a t i v e M o d e r a t e - H i ( ~ 5 0 % ) L o w L o w L o w Breast cancer T N B C Ovarian O v a r i a n cancerc a n c e r Endometrial E n d o m e t r i a l c a cancer n c e r Very little expression on normal cells/tissue

15 FPA150: Phase 1a/1b Clinical Trial to Look for Monotherapy Activity Against B7-H4 Overexpressing Tumors 15 PHASE 1a Dose escalation Any Solid Tumor Initiated March 2018 Exploratory cohort Basket B7-H4+ Tumors Initiated Oct PHASE 1b Expansion; B7-H4+ tumors HR+/HER2- Breast Cancer Triple Negative Breast Cancer Ovarian Cancer Study Objectives Safety Objective response rate and duration Survival Baseline and on-treatment biopsies Endometrial Cancer IHC assay to select patients with B7-H4 expressing tumors in exploratory cohort and Phase 1b Evaluating I-O and chemo combination strategies Additional Cohorts TBD

16 FPT155: First-In-Class CD80-Fc Fusion Protein Engineered for Monotherapy Efficacy by Activating T Cells Through Multiple Pathways 16 Normal T cell activation via CD80 Antigen presenting cell MHC TCR T cell (+) signal FPT155 uses the binding interactions of soluble CD80 to: Directly engage CD28 to enhance its co-stimulatory activity (without super agonism) Block CTLA-4 from competing for endogenous CD80, allowing CD28 signaling to prevail in T cell activation CD80 CD28 CD80 extracellular domain CD80 is a co-stimulatory molecule expressed on antigen presenting cells Human IgG1 Fc

17 T u m o r V o lu m e (M e a n m m 3 S D ) 17 Single Agent mfpt155 Can Induce Tumor Regressions at Low Doses CT26 Tumor Growth Ig G 2 a 0.9 m g /k g m F P T m g /k g (s in g l m F P T m g /k g (s in g l m F P T m g /k g (s in g l migg2 control m F P T m g /k g (s in g l 0.1 mg/kg mmfpt155 F P T One m g /k g (3 d o s 0.2 mg/kg mfpt155 administration 0.6 mg/kg m mfpt155 F P T m g /k g (3 d o s 0.9 mg/kg mmfpt155 F P T m g /k g (3 d o s 0.1 mg/kg mfpt155 Three 0.2 mg/kg mfpt155 administrations 0.3 mg/kg mfpt D a y s p o s t-in o c u la tio n Murine FPT155 (mfpt155) demonstrates monotherapy anti-tumor activity in MC38, EMT6, 4T1, and B16-F10 models

18 mfpt155 Has Synergistic Activity in Combination with anti-pd1 in Large Tumors that are Insensitive to Anti-PD1 18 migg2a CT26 Tumor Growth mfpt155 5/15 rejections anti-pd1 Combination 9/15 rejections

19 19 IND Engine: Unique Platform Generating Novel Therapeutics Comprehensive Libraries of Extracellular Proteins Proprietary Screens Protein Therapeutics Secreted Factors In Clinical Development bemarituzumab (anti-fgfr2b ) Cell-based Screens Antibodies cabiralizumab (anti-csf-1r) Cell Surface Receptors/Ligands In Vivo Screens Soluble Receptors Ligand Traps FPA150 (anti-b7h4) BMS (anti-tim-3) Soluble Extracellular Domains Receptor-Ligand Matching FPT155 (CD80-Fc Fusion)

20 20 Cash and Shares Outstanding Cash, cash equivalents & marketable securities Shares outstanding Estimated cash, cash equivalents & marketable securities, EOY 2018 FY 2018 estimated net cash used in operating activities $321.6 million as of Sept. 30, million as of Sept. 30, 2018 ~ $265 million < $135 million

21 Summary of Financial Results (In Millions Except Per Share Amounts) 21 3Q18 3Q17 Revenue $5.8 $8.3 R&D Expenses $44.7 $42.7 G&A Expenses $9.8 $9.7 Net Loss ($47.2) ($43.3) EPS Basic & Diluted ($1.37) ($1.54)

22 Five Prime News Flow and Milestones Bemarituzumab (FPA144) GASTRIC/GEJ CANCER Cleared Phase 1 safety lead-in to FIGHT chemo combo trial Initiated randomized, global Phase 3 FIGHT trial Present Phase 1 FIGHT trial safety lead-in data at the ASCO GI conference FPA150 (B7-H4 Antibody) Initiated exploratory cohort of FPA150 monotherapy in patients with tumors that overexpress B7-H4 Complete Phase 1a dose escalation, select a dose and initiate Phase 1b expansion Present Phase 1 data at medical conference in 2019 Cabiralizumab PANCREATIC CANCER BMS completes enrollment in randomized Phase 2 trial (2 nd -line pancreatic) combo with OPDIVO + chemo Stand Up To Cancer & BMS initiated randomized Ph 2 front-line maintenance pancreatic trial (GemCaN) FPT155 (CD80-Fc Fusion Protein) Opened enrollment in Phase 1a dose escalation portion of Phase 1 trial in Australia BMS (TIM-3 Antibody) BMS advances trial to Phase 2 BMS presents preclinical poster at SITC 22

23 Thank you NASDAQ:FPRX

Corporate Overview. September 2018 NASDAQ:FPRX

Corporate Overview. September 2018 NASDAQ:FPRX Corporate Overview September 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform

More information

Leerink Immuno-Oncology Roundtable Conference

Leerink Immuno-Oncology Roundtable Conference Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private

More information

Corporate Overview. June 2018 NASDAQ:FPRX

Corporate Overview. June 2018 NASDAQ:FPRX Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

More information

Corporate Overview. March 2018 NASDAQ:FPRX

Corporate Overview. March 2018 NASDAQ:FPRX Corporate Overview March 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act

More information

Corporate Overview. June 2017 NASDAQ:FPRX

Corporate Overview. June 2017 NASDAQ:FPRX Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

More information

Five Prime Therapeutics, Inc. Corporate Overview

Five Prime Therapeutics, Inc. Corporate Overview Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities

More information

Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.

Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer. Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation

More information

More cancer patients are being treated with immunotherapy, but

More cancer patients are being treated with immunotherapy, but Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains

More information

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation

More information

Wells Fargo Healthcare Conference September 6, 2018

Wells Fargo Healthcare Conference September 6, 2018 Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are

More information

33 rd Annual J.P. Morgan Healthcare Conference. January 2015

33 rd Annual J.P. Morgan Healthcare Conference. January 2015 33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.

More information

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains

More information

Third Quarter 2015 Earnings Call. November 9, 2015

Third Quarter 2015 Earnings Call. November 9, 2015 Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

ArQule Jefferies Global Healthcare Conference June 2015

ArQule Jefferies Global Healthcare Conference June 2015 ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning

More information

CORPORATE PRESENTATION

CORPORATE PRESENTATION CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains

More information

LION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology

LION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private

More information

2016 Year-End Results and Conference Call. March 14, 2017

2016 Year-End Results and Conference Call. March 14, 2017 2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform

More information

Citi s 13 th Annual Biotech Conference September 5, 2018

Citi s 13 th Annual Biotech Conference September 5, 2018 Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they

More information

Business Update & Financial Results for Q1 2018

Business Update & Financial Results for Q1 2018 Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains

More information

Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019

Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains

More information

Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)

Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation

More information

NewLink Genetics Corporation

NewLink Genetics Corporation Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking

More information

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking

More information

BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY

BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which

More information

Identification of novel immune regulators of tumor growth using highthroughput

Identification of novel immune regulators of tumor growth using highthroughput Identification of novel immune regulators of tumor growth using highthroughput screening in vivo Tom Brennan 1 Five Prime s Unique Platform Tests Nearly Every Extracellular Protein to Identify Protein

More information

Nektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018

Nektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018 Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the

More information

OncoSec Provides 2018 Business Outlook

OncoSec Provides 2018 Business Outlook January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary

More information

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,

More information

Reimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before

Reimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking

More information

Corporate Overview. July 2016 NASDAQ: CYTR

Corporate Overview. July 2016 NASDAQ: CYTR Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE

More information

FORWARD II PROGRAM UPDATE

FORWARD II PROGRAM UPDATE FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,

More information

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016 ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),

More information

Investor Call. May 19, Nasdaq: IMGN

Investor Call. May 19, Nasdaq: IMGN Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not

More information

INTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY

INTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution

More information

Corporate Presentation

Corporate Presentation Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical

More information

Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018

Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation

More information

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea Antitumor Activity and Safety of FPA144, an ADCCenhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b + Gastric Cancer and Advanced Solid Tumors Jeeyun Lee 1, Johanna Bendell

More information

ArQule CorporateUpdate

ArQule CorporateUpdate ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform

More information

Bank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer

Bank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking

More information

July, ArQule, Inc.

July, ArQule, Inc. July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation

More information

TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018

TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018 NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements

More information

Corporate Presentation October 2018 Nasdaq: ADXS

Corporate Presentation October 2018 Nasdaq: ADXS Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements

More information

National Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.

National Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved. National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.

More information

Dawson James Conference

Dawson James Conference Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding

More information

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,

More information

Leading the Next Wave of Biotech Breakthroughs

Leading the Next Wave of Biotech Breakthroughs Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive

More information

Rexahn Pharmaceuticals Overview

Rexahn Pharmaceuticals Overview Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ

More information

Prostate Cancer Panel. June 2018

Prostate Cancer Panel. June 2018 Prostate Cancer Panel June 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future cash

More information

Idera Pharmaceuticals

Idera Pharmaceuticals Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning

More information

NewLink Genetics Corporation

NewLink Genetics Corporation Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements

More information

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

Investor Meetings October 2018

Investor Meetings October 2018 Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking

More information

REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES

REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within

More information

Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy

Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking

More information

Revolutionizing the Treatment of Cancer

Revolutionizing the Treatment of Cancer Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results

More information

Corporate Overview May 8, 2014

Corporate Overview May 8, 2014 0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements

More information

Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017

Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The

More information

Merck ASCO 2015 Investor Briefing

Merck ASCO 2015 Investor Briefing Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation

More information

ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT

ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE

More information

CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS

CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated

More information

ASCO 2018 Investor Meeting

ASCO 2018 Investor Meeting ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for

More information

Third Quarter 2018 Financial Results. November 1, 2018

Third Quarter 2018 Financial Results. November 1, 2018 Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key

More information

Corporate Presentation March 2016

Corporate Presentation March 2016 Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018

VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018 VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may

More information

Frédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018

Frédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018 Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress

More information

Full Year 2017 Financial Results. February 14, 2018

Full Year 2017 Financial Results. February 14, 2018 Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,

More information

Cowen Annual Healthcare Conference. March 2018

Cowen Annual Healthcare Conference. March 2018 Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,

More information

Targeting the genetic and immunological drivers of cancer

Targeting the genetic and immunological drivers of cancer NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation April 2019 1 Safe Harbor Statement Certain statements contained in this presentation, other than statements

More information

Building a Fully Integrated Biopharmaceutical Company. June 2014

Building a Fully Integrated Biopharmaceutical Company. June 2014 Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation

More information

Revolutionizing the Treatment of Cancer

Revolutionizing the Treatment of Cancer Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JULY 2018 1 Forward-looking statements disclosure This presentation contains forward-looking

More information

Clovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET

Clovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3

More information

Corporate Overview. February 2018 NASDAQ: CYTR

Corporate Overview. February 2018 NASDAQ: CYTR Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER

More information

Targeting the Tumor Locally

Targeting the Tumor Locally Targeting the Tumor Locally Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations are not descriptions of historical facts regarding OncoSec

More information

Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018

Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

The Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018

The Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018 The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about

More information

Revolutionizing the Treatment of Cancer

Revolutionizing the Treatment of Cancer Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may

More information

Aravive Corporate Presentation October 2018

Aravive Corporate Presentation October 2018 Aravive Corporate Presentation October 2018 Important Information Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive s plans, goals, intentions and

More information

Arming the patient s immune system to fight cancer

Arming the patient s immune system to fight cancer Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements

More information

Corporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers

Corporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary

More information

NewLink Genetics Corporation

NewLink Genetics Corporation Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that

More information

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018 MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward

More information

Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018

Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018 Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities

More information

Corporate Overview. May 2017 NASDAQ: CYTR

Corporate Overview. May 2017 NASDAQ: CYTR Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY

More information

PTAC meeting held on 5 & 6 May (minutes for web publishing)

PTAC meeting held on 5 & 6 May (minutes for web publishing) PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and

More information

NOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO

NOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO NOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO ONCOLOGIA MEDICA 1 FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI MILANO PROGRESS AGAINST METASTATIC GC OS in first-line palliative setting Little progress

More information

New Data from Ongoing Melanoma Study and Clinical Development Strategy Update

New Data from Ongoing Melanoma Study and Clinical Development Strategy Update New Data from Ongoing Melanoma Study and Clinical Development Strategy Update Webcast - 29 th / 30 th May 2018 (ASX: IMM, NASDAQ: IMMP) Notice: Forward Looking Statements The purpose of the presentation

More information

Heat Biologics. Corporate Presentation March 9, 2018

Heat Biologics. Corporate Presentation March 9, 2018 Heat Biologics Corporate Presentation March 9, 2018 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements within the meaning of the Private

More information

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014 Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,

More information